Search

Background: OnabotulinumtoxinA and hyaluronic acid are effective in improving moderate to severe facial wrinkles and folds, with treatment selection traditionally based upon facial area.Objectives: This prospective, multicenter, open-label, crossover study evaluated physician-rated efficacy and patient-rated outcomes following moderate to severe facial wrinkles and folds treatment with onabotulinumtoxinA and hyaluronic acid.Methods: 152 subjects (25-65 years) were randomized (1:1) to a treatment-sequence of onabotulinumtoxinA/hyaluronic acid or hyaluronic acid/onabotulinumtoxinA, with initial treatment administered on day 1 and 6 additional visits: week 2 (touch-up); week 4 (crossover); week 6 (touch-up); and weeks 8, 12, and 24 (follow-up).Results: Between 92% and 100% of subjects in each treatment-sequence group exhibited at least some improvement from baseline at each study visit in the Physician Aesthetic Improvement Scale and the Objective Observer and Patient Global Assessments of Improvement, with no significant between-sequence differences. Subjects reported looking 3 to 6 years younger at each visit, with significant improvements in glabellar, lateral canthal, and horizontal forehead lines, and nasolabial folds. Treatments were well tolerated.Conclusions: OnabotulinumtoxinA and hyaluronic acid provide clinically meaningful improvements as rated by physicians, objective observers, and subjects, with clinical synergy in aesthetic effects and duration of response regardless of treatment administration order in subjects seeking improvement in moderate to severe facial wrinkles and folds.Level of Evidence2: [ABSTRACT FROM AUTHOR]

Background: Individuals seeking aesthetic treatment have concerns regarding multiple facial areas.Objectives: Assess the aesthetic impact and satisfaction achieved with a multimodal approach to aesthetic treatment using a combination of minimally invasive treatments.Methods: Prospective, multicenter, rater-blinded, 4-month HARMONY study evaluated patient satisfaction and aesthetic impact of a combination of fillers (VYC-20L, HYC-24L, and HYC-24L+), onabotulinumtoxinA, and bimatoprost. Males and females aged 35 to 65 years received on-label, staged treatment with fillers, as needed per investigator assessment, on day 1, with touch ups allowed on day 14. Bimatoprost was self-administered once daily for 17 weeks. OnabotulinumtoxinA was injected into glabellar lines, crow's feet lines, or both at month 3. Primary effectiveness measure was mean change from baseline on the FACE-Q 10-item Satisfaction with Facial Appearance Overall Scale.Results: Of 100 patients treated, 93 underwent at least the 4-month posttreatment assessment and were assessed for efficacy. The FACE-Q Satisfaction with Facial Appearance Overall Scale total score increased from baseline (41.2) to month 4 (72.9; P < 0.00001; effect size, 2.7). Improvement following multimodal treatment was observed on FACE-Q individual items. Self-perceived age decreased from 0.2 years older than actual age at baseline to 4.6 years younger at month 4. Nearly all patients (99%) rated themselves as improved or much improved on the Global Aesthetic Improvement Scale. Investigator assessments also demonstrated improvement. Mild to moderate adverse events occurred in 42 patients.Conclusions: Minimally invasive, multimodal treatment resulted in improvements in FACE-Q scores and perceived age, indicating a high degree of patient satisfaction and a younger facial appearance.Level Of Evidence4: [ABSTRACT FROM AUTHOR]

Dermal Fillers in Patients on Anticoagulants Anticoagulation is listed as a contraindication in the package inserts of cosmetic dermal fillers. Despite this, they are used every day on anticoagulated patients. [...]

Disclaimer: This study describes an off-label use of Xiaflex. The authors by no means recommend or support the use of any medication for any treatment that exceeds the drug's specified [...]

Abstract Traditional scar revision has addressed issues of thickness with intralesional corticosteroids, superficial contours with dermabrasion or laser resurfacing, and postrepair erythema with hemoglobin-targeted laser therapy. Historically, collagen fillers have [...]

Twenty-three reports included degree of severity: 39.1% (9/23) were mild, 43.4% (10/23) moderate, and 17.4% (4/23) severe (1 inflammatory nodule, 2 noninflammatory nodules, and 1 case of hypersensitivity). In this study, we present the global postmarket safety experience for HA SB KYS sb from 2011 to 2019, with a focus on delayed-onset events, including nodules and inflammatory events, such as hypersensitivity reactions and granulomas. Methods Data were gathered from AE reporting during postmarketing safety surveillance (PMS) between January 2011 and September 2019 for HA SB KYS sb (8 years). [Extracted from the article]

Cellulite is a condition that affects the vast majority of women. Although it is of no danger to one's overall health, cellulite can be psychosocially debilitating. Consequently, much research has been devoted to understanding cellulite and its etiopathogenesis. With additional insights into the underlying causes of its clinical presentation, therapeutic modalities have been developed that offer hope to cellulite sufferers. This review examines evidence for topical treatments, noninvasive energy-based devices, and recently developed minimally invasive interventions that may finally provide a solution. [ABSTRACT FROM AUTHOR]

Mesotherapy is an intradermal or subcutaneous injection of therapeutic agents to induce local effects, and was pioneered in Europe during the 1950s. For the past 2 decades, there has been significant interest in the use of mesotherapy for minimally invasive local fat contouring. Based on the theorized lipolytic effects of the agent phosphatidylcholine, initial attempts involved its injection into subcutaneous tissue. With further studies, however, it became apparent that the activity attributed to phosphatidylcholine mesotherapy was due to the adipolytic effects of deoxycholate, a detergent used to solubilize phosphatidylcholine. Since then, clinical trials have surfaced that demonstrate the efficacy of a proprietary formulation of deoxycholate for local fat contouring. Current trials on mesotherapy with salmeterol, a b-adrenergic agonist and lipolysis stimulator, are underway--with promising preliminary results as well. [ABSTRACT FROM AUTHOR]

This article discusses the use of music intervention during scalp injections to alleviate pain and anxiety in patients. The study found that patients who received music during their PRP treatment reported higher satisfaction and a greater ability to relax compared to those without music. Additionally, the majority of patients in both groups expressed a preference for clinics that offered music during scalp injections. The article also mentions the use of virtual reality as a sensory distraction technique in medical procedures. However, the study has limitations, including a small sample size and a predominantly female cohort. Overall, the findings suggest that music can enhance the patient experience during injection procedures, but further research is needed to explore additional sensory distraction techniques. [Extracted from the article]